Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (56123)	5/13/2000 7:37:00 PM
From: Jack Hartmann	Read Replies (1) \| Respond to of 122087

Hope you don't dress in black in Texas. Those boys don't like flashy dressers <gg>. My Cousin Vinnie had some truths in it. Jack

To: Anthony@Pacific who wrote (56123)	5/15/2000 9:30:00 AM
From: Tassi	Respond to of 122087

Tony for you Good posting from Yahoo " $30 easy by year end SCLN has 4 drugs in the pipleine. SCLN is undervalued based on its future prospects. A Discounted cash flow model shows the accurate and fair price today to be around $25 at a minimum. Zadaxin is approved in 20 countries and has NDa's filed in many more. Zadaxin has a $1.8 billion market potential. Zadaxin recently received Orphan Drug Status by the US FDA. SCLN has large pharmaceutical partnerships formed with Schering Plough and Sigma Tau in Japan and Europe respectively. SCLN has had 10 consecutive quarters of revenue increases. SCLN sought to achieve actual sales in China, which is not a 3rd world country, bc it presented the biggest opportunity. Their plan is to use funds from overseas sales to help finance later stage clinical trials that cost more money. So far they are exeucting their business plan with precision. They have a former FDA commissioner on their Board of Directors. SCLN is based in California, not Hong Kong. SCLN posted 122% sales growth in the most recent quarter and is cash flow positive and will remain so for the remainder of 2000. The homerun markets are US, Japan, and Europe. Once approval occurs here sales will skyrocket and you will see more brokerage coverage. One of the oldest and most respected firms on Wall Street, HC Wainwright, recently issued a very informative and factually correct buy report on SCLN. People should call Ruth Koh at SCLN headquarters for a copy. It is very informative and presents the facts as they are. My Money magazine recently profiled SCLN as one of the best value inevstments available for 2000 and beyond given its situation of exeucting its business plan with precision. IBD profiled SCLN in either Feb or Mar shortly before the Orpahn Drugs Status was conferred upon Zadaxin. *Both Zadaxin and CPX have already progresses thru many clinical trials, and have been proven without a doubt to be both effective and efficacious treatments against HepC, Hep B, HIV, and Cystic Fibrosis. All one has to do is read the clinical results. SMILES pottyman